spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  filgrastim 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 27 Jul 2018
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
Biopharmaceuticals Generics Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jun 2010
Nivestim(TM), a New Biosimilar Filgrastim, is Approved in Europe for the Prevention of Febrile Neutropenia Associated With Chemotherapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
Teva Receives EU Marketing Authorization for TevaGrastim(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Sep 2007
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Nov 2006
GenSci Expects Topical Molgramostim Gel Approval in 2007
Biopharmaceuticals Wound Care Regulatory
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
filgrastim
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.